|
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
|
|
|
| By
Gryssell Rodriguez
,
Airama Albisa
,
Lisel Viņa
,
Ariadna Cuevas
,
Beatriz Garcia
,
Aurora Tamara Garcia
,
Alejandro Portillo
,
Loany Calvo
,
Tania Crombet
,
Gisela Gonzalez
,
Ernesto Chico
|
|
|
|
The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
|
|
|
|
Formulation Studies of an Adsorbed Conjugate Vaccine
|
|
|
| By
Shwu-Maan Lee, PhD
,
Chris Donaldson
|
|
|
|
NeisVac-C is a polysaccharide-protein conjugate vaccine for use against Neisseria meningitidis serogroup C infection. The Phase 1 clinical formulation consisted of physiological saline, thimerosal, and aluminum hydroxide. The long-term stability data for both the PBS and saline formulations are presented in this article.
|
|
|
|
Bridging the Gap in Translational Research for Vaccines
|
|
|
|
Interview with Roger Lias, president and group commercial director at Eden Biodesign, Inc.
|
|
|
|
Preparedness for Pandemic Flu Outbreak
|
|
|
| By
Bikash Chatterjee
|
|
|
|
To succeed in a pandemic, the industry must forge a preparedness plan to ensure adequate vaccines.
|
|
|
|
Developing Plasmid DNA Vaccines
|
|
|
|
Interview with Magda Marquet, co-CEO and co-president of Althea Technologies
|
|
|
|
Vaccines Incorporating Toll-Like Receptor Ligands
|
|
|
| By
Alan Shaw, PhD
|
|
|
|
This article discusses the production process of the major influenza antigen, hemagglutinin (HA), by rDNA methods in E. coli.
|
|
|
|
Developing and Manufacturing Attenuated Live Bacterial Vaccines
|
|
|
| By
Guido Dietrich
,
Andre Collioud
,
Simon A. Rothen
|
|
|
|
There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
|
|
|
